My Treatment Approach to Hairy Cell Leukemia
Authors:
- 1 January 2012
- journal article
- practice guideline
- Published by Elsevier in Mayo Clinic Proceedings
- Vol. 87 (1) , 67-76
Abstract
No abstract availableKeywords
This publication has 48 references indexed in Scilit:
- Improved Survival with Vemurafenib in Melanoma with BRAF V600E MutationNew England Journal of Medicine, 2011
- BRAFMutations in Hairy-Cell LeukemiaNew England Journal of Medicine, 2011
- Phase II Trial of Recombinant Immunotoxin RFB4(dsFv)-PE38 (BL22) in Patients With Hairy Cell LeukemiaJournal of Clinical Oncology, 2009
- Long‐term follow‐up of 233 patients with hairy cell leukaemia, treated initially with pentostatin or cladribine, at a median of 16 years from diagnosisBritish Journal of Haematology, 2009
- Rituximab as treatment for minimal residual disease in hairy cell leukaemia: extended follow‐upBritish Journal of Haematology, 2008
- Rituximab in patients with hairy cell leukemia relapsing after treatment with 2-chlorodeoxyadenosine (SAKK 31/98)Haematologica, 2008
- Eradication of minimal residual disease in hairy cell leukemiaBlood, 2006
- Long-term outcome with pentostatin treatment in hairy cell leukemia patients. A French retrospective study of 238 patientsLeukemia, 2003
- Lasting Remissions in Hairy-Cell Leukemia Induced by a Single Infusion of 2-ChlorodeoxyadenosineNew England Journal of Medicine, 1990
- Alpha Interferon for Induction of Remission in Hairy-Cell LeukemiaNew England Journal of Medicine, 1984